CLAIMS

1. A compound of Formula (I):



wherein:

R^1 is selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted cycloalkyl, an optionally substituted cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(alkyl), an optionally substituted cycloalkenyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl), hydroxy, an optionally substituted alkoxy, cyano, an optionally substituted C-carboxy, an optionally substituted N-amido, an optionally substituted urea, nitro, an optionally substituted sulfenyl, an optionally substituted haloalkyl, amino, an optionally substituted mono-substituted amino group, an optionally substituted di-substituted amino group and $-(CR^{1a1}R^{1a2})q-R^{1b}$, wherein q is 1, 2, 3, 4, 5 or 6, each R^{1a1} and each R^{1a2} are independently hydrogen, halogen or an unsubstituted alkyl, and R^{1b} is selected from the group consisting of hydroxy, an optionally substituted N-amido, an optionally substituted N-sulfinamido, an optionally substituted N-sulfonamido, an optionally substituted urea, an optionally substituted sulfenyl, amino, an optionally substituted mono-substituted amino group and an optionally substituted di-substituted amino group;

Y^1, Y^2 and Y^3 are independently C or N,

provided that when Y^1 is C, then R^{2a} is selected from the group consisting of hydrogen, halogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(alkyl), an optionally

substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl), hydroxy, an optionally substituted alkoxy, cyano, nitro, an optionally substituted sulfenyl, amino, an optionally substituted mono-substituted amino group and an optionally substituted di-substituted amino group, and when Y^1 is N, then R^{2a} is absent,

provided that when Y^2 is C, then R^{2b} is selected from the group consisting of hydrogen, halogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl), hydroxy, an optionally substituted alkoxy, cyano, nitro, an optionally substituted sulfenyl, amino, an optionally substituted mono-substituted amino group and an optionally substituted di-substituted amino group, and when Y^2 is N, then R^{2b} is absent,

provided that when Y^3 is C, then R^{2c} is selected from the group consisting of hydrogen, halogen, an optionally substituted alkyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl), hydroxy, an optionally substituted alkoxy, cyano, nitro, an optionally substituted sulfenyl, amino, an optionally substituted mono-substituted amino group and an optionally substituted di-substituted amino group, and when Y^3 is N, then R^{2c} is absent,

each R^{3a}, each R^{3b}, R^{3c}, R^{3d}, each R^{3e}, each R^{3f}, R^{3g}, R^{3h}, R^{3i} and R^{3j} are independently selected from the group consisting of hydrogen, halogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclyl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) hydroxy, an optionally substituted alkoxy, an optionally substituted haloalkoxy, cyano, an optionally substituted N-amido, an optionally substituted C-carboxy, an

optionally substituted oxime, an optionally substituted acyl hydrozone, an optionally substituted sulfenyl, an optionally substituted sulfinyl, an optionally substituted sulfonyl, amino, an optionally substituted mono-substituted amino group, an optionally substituted di-substituted amino group and -(CH_2)r-R^{3k}, wherein r is 1, 2, 3, 4, 5 or 6, and R^{3k} is selected from the group consisting of halo, hydroxy, cyano, an optionally substituted heteroaryl, an optionally substituted alkoxy, an optionally substituted sulfenyl and an optionally substituted hydrazine;

each R^{4a} and each R^{4b} are independently hydrogen, deuterium or an optionally substituted alkyl;

R^{5a}, R^{5b}, R^{5c}, R^{5e}, R^{5f}, R^{5g} and R^{5h} are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy; or

R^{5b} and R^{5c} are taken together to form an optionally substituted cycloalkyl, an optionally substituted aryl or an optionally substituted heterocyclyl, and R^{5a}, R^{5e}, R^{5f}, R^{5g} and R^{5h} are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy; or

R^{5f} and R^{5g} are taken together to form an optionally substituted cycloalkyl, an optionally substituted aryl or an optionally substituted heterocyclyl, R^{5a}, R^{5b}, R^{5c}, R^{5e} and R^{5h} are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy; or

R^{5b} and R^{5c} are taken together to form an optionally substituted cycloalkyl, an optionally substituted aryl or an optionally substituted heterocyclyl, and R^{5f} and R^{5g} are taken together to form an optionally substituted cycloalkyl, an optionally substituted aryl or an optionally substituted heterocyclyl, and R^{5a}, R^{5e} and R^{5h} are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy; or

R^{5b} and R^{5g} are connected via Y^5, wherein Y^5 is $(CR^{5i}R^{5j})s$, wherein s is 1, 2 or 3, and each R^{5i} and each R^{5j} are independently hydrogen, halogen or an unsubstituted alkyl, and R^{5a}, R^{5c}, R^{5e}, R^{5f} and R^{5h} are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy;

R^{5c} and R^{5e} are connected via Y^6, wherein Y^6 is $(CR^{5k}R^{5l})t$, wherein t is 1, 2 or 3, and each R^{5j} and each R^{5l} are independently hydrogen, halogen or an unsubstituted alkyl, and R^{5a}, R^{5b}, R^{5f}, R^{5g} and R^{5h} are independently selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy;

R^6 is an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl;

A^1 is selected from the group consisting of an optionally substituted C_{3-10} cycloalkyl, an optionally substituted C_{3-10} cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl and an optionally substituted heterocyclyl;

X^1 is hydrogen, O or S, provided that when X^1 is hydrogen, then ------- is a single bond, and when X^1 is O or S, then ------- is a double bond;

X^2 is O or S;

Y^4 is $C(Y^{1a})$, C or N,

Y^{1a} is selected from the group consisting of hydrogen, halogen, unsubstituted C_{1-4} alkyl and -O-C_{1-4} alkyl;

-------- is a single or double bond;

wherein when Y^4 is $C(Y^{1a})$ and -------- is a single bond, then R^{5d} is selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy,

wherein when Y^4 is C and -------- is a double bond, then R^{5d} is absent, and

wherein when Y^4 is N, then -------- is a single bond and R^{5d} is selected from the group consisting of hydrogen, an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted alkynyl, an optionally substituted cycloalkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted cycloalkyl(alkyl), an optionally substituted aryl(alkyl), an optionally substituted heteroaryl(alkyl), an optionally substituted heterocyclyl(alkyl) and an optionally substituted C-carboxy;

m is 0, 1 or 2;

n is 0, 1 or 2; and

p is 1, 2 or 3.

2. The compound of Claim 1, wherein m is 1 or 2; n is 0 or 1; and R^{3a}, R^{3b}, R^{3c}, R^{3d}, R^{3e}, R^{3f}, R^{3g}, R^{3h}, R^{3i} and R^{3j} are each hydrogen.

3. The compound of any one of Claims 1-2, wherein X^1 is hydrogen, and ------- is a single bond.

4. The compound of any one of Claims 1-2, wherein X^1 is O, and ------- is a double bond.

5. The compound of any one of Claims 1-4, wherein R^1 is H, CN, an optionally substituted cycloalkyl or an optionally substituted cycloalkenyl.

6. The compound of any one of Claims 1-4, wherein R^1 is an optionally substituted aryl, an optionally substituted heteroaryl or an optionally substituted heterocyclyl.

7. The compound of any one of Claims 1-6, wherein Y^1 is C; and R^{2a} is hydrogen.

8. The compound of any one of Claims 1-6, wherein Y^1 is N and R^{2a} is absent.

9. The compound of any one of Claims 1-8, wherein Y^2 is C; R^{2b} is hydrogen; Y^3 is C; and R^{2c} is hydrogen.

10. The compound of any one of Claims 1-9, wherein p is 1; each R^{4a} and each R^{4b} are each hydrogen; and X^2 is O.

11. The compound of any one of Claims 1-10, wherein Y^4 is $C(Y^{1a})$; -------- is a single bond; and R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g} and R^{5h} are each hydrogen; or wherein Y^4 is C, -------- is a double bond; R^{5d} is absent; and R^{5a}, R^{5b}, R^{5c}, R^{5e}, R^{5f}, R^{5g} and R^{5h} are each hydrogen.

12. The compound of any one of Claims 1-10, wherein Y^4 is N; -------- is a single bond; and R^{5a}, R^{5b}, R^{5c}, R^{5d}, R^{5e}, R^{5f}, R^{5g} and R^{5h} are each hydrogen.

13. The compound of any one of Claims 1-12, wherein A^1 is an optionally substituted C_{3-10} cycloalkyl.

14. The compound of any one of Claims 1-12, wherein A^1 is an optionally substituted aryl.

15. The compound of any one of Claims 1-12, wherein A^1 is an optionally substituted heteroaryl.

16. The compound of any one of Claims 1-15, wherein R^6 is an optionally substituted aryl.

17. The compound of any one of Claims 1-15, wherein R^6 is an optionally substituted heteroaryl.

18. The compound of Claim 1, selected from the group consisting of:


,


,


,


,


,


,


,


,


,

,

,

,

,

,

,

,



,



,



,



,



,



,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,


,

,

,

,

,

,

,

,

(*S*)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2-(3-(2-methylbenzo[d]oxazol-5-yl)-1H-indazol-5-yl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-7-(2-(4-(4-(1-cyclopropyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2-(3-(6-isopropoxypyridin-3-yl)-1H-pyrazolo[4,3-b]pyridin-5-yl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2-(3-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazol-5-yl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-2-(3-(6-(difluoromethyl)pyridin-3-yl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-2-(3-(2-(difluoromethyl)pyrimidin-5-yl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(5S)-2-(3-(6-(1-hydroxypropan-2-yl)pyridin-3-yl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-2-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-7-(2-(4-(5-(1-methyl-1H-1,2,4-triazol-3-yl)thiazol-2-yl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2-(3-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-2-(3-(3,6-dihydro-2H-pyran-4-yl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-2-(3-(4-methoxyphenyl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-4-(5-(7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)benzonitrile;

(S)-2-methoxy-4-(5-(7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)benzonitrile;

(S)-2-methoxy-5-(5-(7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)benzonitrile;

(S)-2-(3-(1-acetylpiperidin-4-yl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-2-(3-(1-(2-hydroxyacetyl)piperidin-4-yl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-5-(5-(7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)-2-(trifluoromethoxy)benzonitrile;

(S)-5-(5-(7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)-2-(trifluoromethyl)benzonitrile;

(S)-2-(3-(4-methoxypiperidin-1-yl)-1H-indazol-5-yl)-7-(2-(4-(4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-2,7-diazaspiro[4.4]nonan-1-one;

(S)-5-(4-(1-(2-(7-(3-(6-isopropoxypyridin-3-yl)-1H-indazol-5-yl)-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)acetyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one;

(S)-4-(5-(7-(2-(4-(4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)benzonitrile;

(S)-3-(5-(7-(2-(4-(4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)benzonitrile;

(S)-2-methoxy-4-(5-(7-(2-(4-(4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)benzonitrile;

(S)-2-methoxy-5-(5-(7-(2-(4-(4-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl)-3,6-dihydropyridin-1(2H)-yl)-2-oxoethyl)-1-oxo-2,7-diazaspiro[4.4]nonan-2-yl)-1H-indazol-3-yl)benzonitrile;

(S)-3-methyl-5-(4-(1-(2-(7-(3-(2-methylbenzo[d]oxazol-5-yl)-1H-indazol-5-yl)-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)acetyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1,3,4-oxadiazol-2(3H)-one;

(S)-3-methyl-5-(4-(1-(2-(7-(3-morpholino-1H-indazol-5-yl)-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)acetyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1,3,4-oxadiazol-2(3H)-one;

(S)-3-methyl-5-(4-(1-(2-(6-oxo-7-(3-(tetrahydro-2H-pyran-4-yl)-1H-indazol-5-yl)-2,7-diazaspiro[4.4]nonan-2-yl)acetyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-1,3,4-oxadiazol-2(3H)-one;

(S)-5-(4-(1-(2-(7-(3-(1-acetylpiperidin-4-yl)-1H-indazol-5-yl)-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)acetyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one; and

(S)-5-(4-(1-(2-(7-(3-(4-methoxypiperidin-1-yl)-1H-indazol-5-yl)-6-oxo-2,7-diazaspiro[4.4]nonan-2-yl)acetyl)-1,2,3,6-tetrahydropyridin-4-yl)phenyl)-3-methyl-1,3,4-oxadiazol-2(3H)-one,

or a pharmaceutically salt of any of the foregoing.

19. A compound selected from the group consisting of:  ,  ,  ,  and  , or a pharmaceutically salt of any of the foregoing.

20. A pharmaceutical composition comprising an effective amount of a compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient, or combination thereof.

21. Use of an effective amount of a compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 20 in the manufacture of a medicament for ameliorating or treating a cancer, wherein the cancer is selected from the group consisting of a lung cancer, a pancreatic cancer, a colon cancer, a myeloid leukemia, a thyroid cancer, myelodysplastic syndrome (MDS), a bladder carcinoma, an epidermal carcinoma, a melanoma, a breast cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer, a cancer of mesenchymal origin, a sarcoma, a tetracarcinoma, a neuroblastoma, a kidney carcinoma, a hepatoma, a non-Hodgkin's lymphoma, a multiple myeloma, an anaplastic thyroid carcinoma and neurofibromatosis.

22. Use of an effective amount of a compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 20 in the manufacture of a medicament for inhibiting replication of a malignant growth or a tumor,

wherein the malignant growth or tumor is due to a cancer is selected from the group consisting of a lung cancer, a pancreatic cancer, a colon cancer, a myeloid leukemia, a thyroid cancer, myelodysplastic syndrome (MDS), a bladder carcinoma, an epidermal carcinoma, a melanoma, a breast cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer, a cancer of mesenchymal origin, a sarcoma, a tetracarcinoma, a neuroblastoma, a kidney carcinoma, a hepatoma, a non-Hodgkin's lymphoma, a multiple myeloma, an anaplastic thyroid carcinoma and neurofibromatosis.

23. Use of an effective amount of a compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 20 in the manufacture of a medicament for ameliorating or treating a cancer, wherein the malignant growth or tumor is due to a cancer is selected from the group consisting of a lung cancer, a pancreatic cancer, a colon cancer, a myeloid leukemia, a thyroid cancer, myelodysplastic syndrome (MDS), a bladder carcinoma, an epidermal carcinoma, a melanoma, a breast cancer, a prostate cancer, a head and neck cancer, an ovarian cancer, a brain cancer, a cancer of mesenchymal origin, a sarcoma, a tetracarcinoma, a neuroblastoma, a kidney carcinoma, a hepatoma, a non-Hodgkin's lymphoma, a multiple myeloma, an anaplastic thyroid carcinoma and neurofibromatosis.